No Detail Found!

Frequency of no-reflow in patients undergoing primary percutaneous coronary intervention and the impact of intracoronary adrenaline and tirofiban on timi flow

Author(s)
Ikramullah Department of Cardiology, Lady reading Hospital Peshawar-,,Pakistan
Hamidullah Department of Cardiology, Lady reading Hospital Peshawar-,,Pakistan
Farooq Ahmad Department of Cardiology, Khyber Teaching Hospital Peshawar-,,Pakistan
Sajjad Khan Department of Cardiology, Lady reading Hospital Peshawar-,,Pakistan
Hafiz Adil Bilal Department of Cardiology, Lady reading Hospital Peshawar-,,Pakistan
Samiurehman Department of Cardiology, Lady reading Hospital Peshawar-,,Pakistan
Abstract
Background: Coronary interventions, including percutaneous coronary intervention (PCI), have significantly improved management of coronary artery disease by restoration of coronary blood flow to myocardium. However, despite of so many advancements in PCI procedural techniques, there is still a significant and challenging complication known as the "no-reflow" phenomenon exists which worst effect the PPCI outcome. Methods: It was Cross sectional study conducted at Department of Cardiology, Lady Reading Hospital Peshawar. Study was conducted from 1/1/2023 to 30/6/2023 for six months. All patients who developed no reflow were subjected to intracoronary Tirofiban. Those who do not responded to Tirofiban were given intracoronary adrenalin and effect was noted. Data were analyzed using SPSS Version 23.0. Mean and standard deviation were calculated for quantitative variables like age. Frequencies and percentages were calculated for categorical variables like gender. The p-value less than 0.05 was considered significant. Results: Among 151 participants, 18% experienced the no-reflow phenomenon. Intracoronary adrenaline and Tirofiban individually showed a significant positive impact on TIMI flow. It was found that 40% patients with no reflow responded to Tirofiban administration. Remaining patients with no reflow were subjected to intracoronary adrenalin therapy and 74% of these patients had improved TIMI flow. It was also found that combine effect of Tirofiban and adrenalin was found in 84% of patients. Conclusion: No reflow phenomenon is common finding in Primary PCI and can be effectively managed by Tirofiban and intracoronary adrenalin administration in most cases.
Publication Details
Page(s) 510-513
Published Journal: Journal of Ayub Medical College, Volume: 36, Issue: 3, Year: 2024

Request the full text from PASTIC

Keywords
No reflow, TIMI, STEMI, PPCI
References
Kocayigit I,Yaylaci S,Osken A,Aydın E,Sahinkus S,Can Y .2019 .Comparison of effects of thrombolytic therapy and primary percutaneous coronary intervention in elderly patients with acute ST-segment elevation myocardial infarction on inhospital, six-month, and one-year mortality. Arch Med Sci Atheroscler Dis, 4 : e82-8.
.2012 .Association of bleeding and in-hospital mortality in black and white patients with ST-segment elevation myocardial infarction receiving reperfusion. Circulation, 125(14) : 1727-34.
.2010 .Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med, 362(23) : 2155-65.
Terkelsen CJ,Sørensen JT,Maeng M,Jensen LO,Tilsted HH,Vach W .2010 .System de-lay and mortality among patients with STEMI treated with primary percutaneous coronary intervention. JAMA, 304(7) : 763-71.
Armstrong PW,Boden WE .2011 .Reperfusion paradox in STsegment elevation myocardial infarction. Ann Intern Med, 155(6) : 389-91.
Yudi MB,Sharma SK,Tang GHL,Kini A .2018 .Coronary angiography and percutaneous coronary intervention after transcatheter aortic valve replacement. J Am Coll Cardiol, 71(12) : 1360-78.
.2008 .Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention. Circulation, 117(24) : 3152-6.
Galasso G,Schiekofer S,D'Anna C,Gioia GD,Piccolo R,Niglio T .2014 .No-reflow phenomenon: pathophysiology, diagnosis, prevention, and treatment. A review of the current literature and future perspectives. Angiology, 65(3) : 180-9.
Reffelmann T,Kloner RA. Kloner .2002 .The “no-reflow” phenomenon: basic science and clinical correlates. Heart, 87(2) : 162-8.
Kelly RV,Cohen MG,Runge MS,Stouffer GA .2004 .The no-reflow phenomenon in coronary arteries. J Thromb Haemost, 2(11) : 1903-7.
Ito H .2006 .No-reflow phenomenon and prognosis in patients with acute myocardial infarction. Nat Clin Pract Cardiovasc Med, 3(9) : 499-506.
Jaffe R,Charron T,Puley G,Dick A,Strauss BH .2008 .Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention. Circulation, 117(24) : 3152-6.
Wang L,Cheng Z,Gu Y,Peng D Y .2015 .Short-term effects of verapamil and diltiazem in the treatment of no reflow phenomenon: a meta-analysis of randomized controlled trials. Biomed Res Int, : 382086.
Arab TA,Rafik R,Etriby AL .2016 .Efficacy and safety of local intracoronary drug delivery in treatment of no-reflow phenomenon: a pilot study. J Interven Cardiol, 29(5) : 496-504.
Rao PS. Bhardwaj R,Nath RK .2023 .No reflow phenomenon in CAD patients after percutaneous coronary intervention: A prospective hospital based observational study. Indian Heart J, 75(2) : 156-9.
Yang L,Cong H,Lu Y,Chen X,Liu Y. .2020 .Prediction of noreflow phenomenon in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Medicine (Baltimore), 99(26) : e20152.
Shahri BM .2020 .Vojdanparast, Coronary No-reflow Phenomenon: A Review of Therapeutic Pharmacological Agents. Razavi Int J Med, 8(1234) : 1-7.
Akpek M,Sahin O,Sarli B,Baktir AO,Saglam H,Urkmez S .2015 .Acute Effects of Intracoronary Tirofiban on No-Reflow Phenomena in Patients With ST-Segment Elevated Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Angiology, 66(6) : 560-7.
Aksu T,Guler TE,Colak A,Baysal E,Durukan M,Sen T .2015 .Intracoronary epinephrine in the treatment of refractory noreflow after primary percutaneous coronary intervention: a retrospective study. BMC Cardiovasc Disord, 15 : 10.
0

Citations

0

Downloads

69

Views